Increase in the prevalence of chronic idiopathic constipation due to change in lifestyle and food habits, rise in awareness about the CIC treatment, increase in the demand for CIC drugs, and availability of the over-the-counter CIC drugs in the market are driving the chronic idiopathic constipation treatment market. Moreover, various pipeline drugs for the CIC treatment and frequent product approvals from various drug regulatory bodies are propelling the chronic idiopathic constipation treatment market. However, lack of physiological symptoms for the disease and less number of drugs available for CIC treatment are the factors anticipated to hinder the growth of Chronic Idiopathic Constipation Treatment Market
Global Chronic Idiopathic Constipation Treatment Market
Chronic idiopathic constipation is a functional gastrointestinal disorder which leads to difficulty in defecating. It is a more chronic or severe condition and the symptoms of the disease include bloating, abdominal discomfort, hard stool, incomplete evacuation, gastric pain, and strain during the bowel movement. It is an idiopathic condition due to the causes of the disease are unclear, however, it may cause due to psychological, neurological, and psychosomatic conditions. Chronic idiopathic constipation is majorly caused in the adults or geriatric people. Diagnosis of CIC is difficult due to the lack of physiological causes and physicians look for symptoms like weight, blood in stool, and low blood count among others.
Chronic idiopathic constipation treatment market is segmented on the basis of the drug class, route of administration, distribution mode, and distribution channel
Based on the drug class, Chronic idiopathic constipation treatment market is segmented into the following:
- Bulk-forming agents
- Chloride channel activators
- Osmotic products
Based on the route of administration, Chronic idiopathic constipation treatment market is segmented into the following:
Based on the distribution mode, Chronic idiopathic constipation treatment market is segmented into the following:
- Prescription mode
- Over-the-counter drugs
Based on the distribution channel, Chronic idiopathic constipation treatment market is segmented into the following:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Drug Stores
Chronic idiopathic constipation Treatment market is growing at a significant CAGR owing to recent product approvals and competitors focus on the development of newer drugs for CIC treatment. Moreover, increase in the prevalence of chronic idiopathic constipation cases also expected to propel the market revenue over the forecast period. Acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by the companies for increasing their revenue share in the market. For instance, In January 2017, FDA approved Tulane manufactured by Synergy Pharmaceuticals used in the treatment of chronic idiopathic constipation.
Geographically, Chronic Idiopathic Constipation Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America has a significant share in chronic idiopathic constipation treatment market owing to increase in the prevalence if CIC disease (according to National Institute of Health, approximately 63 Mn people affected with CIC in U.S.), change in lifestyle, recent FDA approvals for CIC treatment drugs, an increase in healthcare expenditure. In Europe, increase in ageing population, rise in R&D activities for CIC treatments, availability of over-the-counter CIC drugs, an increase in per capita income might bolster the chronic idiopathic constipation treatment market. However, Asia Pacific exhibiting lucrative growth owing to the rise in geriatric population, an increase in adoption of CIC treatments.
Some of the players in Chronic Idiopathic Constipation Treatment Market are GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Allergan Plc. (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma, Inc. (Japan), synergy pharmaceuticals, Inc. (U.S.), Sanofi S.A. (France), and Pfizer, Inc. (U.S.) to name a few.
- In September 2017, Astellas Pharma, Inc. submitted the Supplemental new drug application for Linaclotide for patients with chronic idiopathic constipation in Japan
- In January 2017, FDA approved the Linzess for the treatment of chronic idiopathic constipation manufactured by Allergan Plc. and Ironwood Pharmaceuticals, Inc.
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario